The role of glucocorticoid action in the pathophysiology of the Metabolic Syndrome

Nutrition and Metabolism

Volumn 2, Issue , 2005, Pages

  Wang, Minghan ^a  

^a AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; ANTIHYPERTENSIVE AGENT; CARBENOXOLONE; GLUCOCORTICOID; GLUCOCORTICOID ANTAGONIST; GLYCYRRHETINIC ACID; INSULIN SENSITIZING AGENT; LIPID; METYRAPONE; PROTEIN; TRANSCORTIN; UNCLASSIFIED DRUG;

BLOOD PRESSURE; BODY WEIGHT; CATALYSIS; CIRCADIAN RHYTHM; CLINICAL FEATURE; DISEASE ASSOCIATION; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DRUG USE; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC REGULATION; GLUCONEOGENESIS; HEMOCONCENTRATION; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE DETERMINATION; HORMONE METABOLISM; HORMONE RELEASE; HUMAN; INSULIN RESISTANCE; LIPID METABOLISM; METABOLIC SYNDROME X; METABOLISM; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; PATIENT; REGULATORY MECHANISM; REVIEW;

EID: 15444366462     PISSN: 17437075     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-7075-2-3     Document Type: Review

References (180)

1. Reaven GM: Role of insulin resistance in human disease. Banting lecture. Diabetes 1988, 37(12):1595-1607.
2. Reaven GM: Insulin resistance, hyperinsulinemia, hypertriglyceridemia, and hypertension. Parallels between human disease and rodent models. Diabetes Care 1991, 14(3):195-202.
3. DeFronzo RA, Ferrannini E: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care 1991, 14(3):173-194.
4. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Final Report. Circulation 2002, 106:3143-3421.
5. World Health Organization: Definition, diagnosis and classification of diabetes mellitus and its complications: report of a WHO Consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization. 1999 [http://whqlibdoc.who.int/hq/1999/WHO_NCD_NCS_99.2. pdf].
6. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15(7):539-553.
7. Grundy SM, Brewer HB Jr, Cleeman JI, Smith SC Jr, Lenfant C, For the Conference participants: Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109(3):433-438.
8. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002, 287(3):356-359.
9. Trevisan M, Liu J, Bahsas FB, Menotti A: Syndrome X and mortality: a population-based study. Risk Factor and Life Expectancy Research Group. Am J Epidemiol 1998, 148(10):958-966.
10. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M, Taskinen MR, Groop L: Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001, 24(4):683-689.
11. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M: Diagnosis and complications of Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab 2003, 88(12):5593-5602.
12. Magiakou MA, Mastorakos G, Zachman K, Chrousos GP: Blood pressure in children and adolescents with Cushing's syndrome before and after surgical cure. J Clin Endocrinol Metab 1997, 82(6):1734-1738.
13. Fallo F, Sonino N, Barzon L, Pistorello M, Pagotto U, Paoletta A, Boscaro M: Effect of surgical treatment on hypertension in Cushing's syndrome. Am J Hypertens 1996, 9(1):77-80.
14. Davis GF: Adverse effects of corticosteroids: II. Systemic. Clin Dermatol 1986, 4(1):161-169.
15. Gallant C, Kenny P: Oral glucocorticoids and their complications. J Am Acad Dermatol 1986, 14(2 Pt 1):161-177.
16. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD: Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol 2000, 106(4):651-659.
17. Srivastava LS, Werk EE Jr, Thrasher K, Sholiton LJ, Kozera R, Nolten W, Knowles HC Jr: Plasma cortisone concentration as measured by radioimmunoassay. J Clin Endocrinol Metab 1973, 36(5):937-943.
18. Reach G, Nakane H, Nakane Y, Auzan C, Corvol P: Cortisol metabolism and excretion in the isolated perfused rat kidney. Steroids 1977, 30(5):621-635.
19. Whitworth JA, Stewart PM, Burt D, Atherden SM, Edwards CR: The kidney is the major site of cortisone production in man. Clin Endocrinol (Oxf) 1989, 31(3):355-361.
20. Walker EA, Stewart PM: 11β-hydroxysteroid dehydrogenase: unexpected connections. Trends Endocrinol Metab 2003, 14(7):334-339.
21. Bujalska I, Shimojo M, Howie A, Stewart PM: Human 11β-hydroxysteroid dehydrogenase: studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue. Steroids 1997, 62(1):77-82.
22. Walker BR, Campbell JC, Fraser R, Stewart PM, Edwards CR: Mineralocorticoid excess and inhibition of 11β-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome. Clin Endocrinol (Oxf) 1992, 37(6):483-492.
23. Johansson A, Andrew R, Forsberg H, Cederquist K, Walker BR, Olsson T: Glucocorticoid metabolism and adrenocortical reactivity to ACTH in myotonic dystrophy. J Clin Endocrinol Metab 2001, 86(9):4276-4283.
24. Lu XY, Shieh KR, Kabbaj M, Barsh GS, Akil H, Watson SJ: Diurnal rhythm of agouti-related protein and its relation to corticosterone and food intake. Endocrinology 2002, 143(10):3905-3915.
25. Delbende C, Delarue C, Lefebvre H, Bunel DT, Szafarczyk A, Mocaer E, Kamoun A, Jegou S, Vaudry H: Glucocorticoids, transmitters and stress. Br J Psychiatry Suppl 1992, 160(15):24-35.
26. Dunn JF, Nisula BC, Rodbard D: Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. J Clin Endocrinol Metab 1981, 53(1):58-68.
27. Weiser JN, Do YS, Feldman D: Synthesis and secretion of corticosteroid-binding globulin by rat liver. A source of heterogeneity of hepatic corticosteroid-binders. J Clin Invest 1979, 63(3):461-467.
28. Pemberton PA, Stein PE, Pepys MB, Potter JM, Carrell RW: Hormone binding globulins undergo serpin conformational change in inflammation. Nature 1988, 336(6196):257-258.
29. Hammond GL, Smith CL, Paterson NA, Sibbald WJ: A role for corticosteroid-binding globulin in delivery of cortisol to activated neutrophils. J Clin Endocrinol Metab 1990, 71(1):34-39.
30. Grasa MM, Cabot C, Balada F, Virgili J, Sanchis D, Monserrat C, Fernandez-Lopez JA, Remesar X, Alemany M: Corticosterone binding to tissues of adrenalectomized lean and obese Zucker rats. Horm Metab Res 1998, 30(12):699-704.
31. Vogeser M, Felbinger TW, Kilger E, Roll W, Fraunberger P, Jacob K: Corticosteroid-binding globulin and free cortisol in the early postoperative period after cardiac surgery. Clin Biochem 1999, 32(3):213-216.
32. Bernier J, Jobin N, Emptoz-Bonneton A, Pugeat MM, Garrel DR: Decreased corticosteroid-binding globulin in burn patients: relationship with interleukin-6 and fat in nutritional support. Crit Care Med 1998, 26(3):452-460.
33. Tinnikov AA, Legan MV, Sheveluk NA, Cvetovskaya GA, Naumenko SE, Sidelnikov SG: Corticosteroid and immune responses to cardiac surgery. Steroids 1996, 61(7):411-415.
34. Aranoff G, Rosler A: Urinary tetrahydrocortisone and tetrahydrocortisol glucosiduronates in normal newborns, children and adults. Acta Endocrinol (Copenh) 1980, 94(3):371-375.
35. Bamberger CM, Schulte HM, Chrousos GP: Molecular determinants of glucocorticoid receptor function and tissue sensitivity to glucocorticoids. Endocr Rev 1996, 17(3):245-261.
36. Schacke H, Rehwinkel H: Dissociated glucocorticoid receptor ligands. Curr Opin Investig Drugs 2004, 5(5):524-528.
37. Zhang XK, Dong JM, Chiu JF: Regulation of alpha-fetoprotein gene expression by antagonism between AP-1 and the glucocorticoid receptor at their overlapping binding site. J Biol Chem 1991, 266(13):8248-8254.
38. Ray A, Prefontaine KE: Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor. Proc Natl Acad Sci U S A 1994, 91(2):752-756.
39. Nissen RM, Yamamoto KR: The glucocorticoid receptor inhibits NFkappaB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain. Genes Dev 2000, 14(18):2314-2329.
40. Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr: Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995, 270(5234):283-286.
41. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M: Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995, 270(5234):286-290.
42. Gaunitz F, Heise K, Schumann R, Gebhardt R: Glucocorticoid induced expression of glutamine synthetase in hepatoma cells. Biochem Biophys Res Commun 2002, 296(4):1026-1032.
43. Becker PB, Gloss B, Schmid W, Strahle U, Schutz G: In vivo protein-DNA interactions in a glucocorticoid response element require the presence of the hormone. Nature 1986, 324(6098):686-688.
44. Jantzen HM, Strahle U, Gloss B, Stewart F, Schmid W, Boshart M, Miksicek R, Schutz G: Cooperativity of glucocorticoid response elements located far upstream of the tyrosine aminotransferase gene. Cell 1987, 49(1):29-38.
45. Danesch U, Gloss B, Schmid W, Schutz G, Schule R, Renkawitz R: Glucocorticoid induction of the rat tryptophan oxygenase gene is mediated by two widely separated glucocorticoidresponsive elements. EMBO J 1987, 6(3):625-630.
46. Imai E, Stromstedt PE, Quinn PG, Carlstedt-Duke J, Gustafsson JA, Granner DK: Characterization of a complex glucocorticoid response unit in the phosphoenolpyruvate carboxykinase gene. Mol Cell Biol 1990, 10(9):4712-4719.
47. Schmoll D, Allan BB, Burchell A: Cloning and sequencing of the 5′ region of the human glucose-6-phosphatase gene: transcriptional regulation by cAMP, insulin and glucocorticoids in H4IIE hepatoma cells. FEBS Lett 1996, 383(1-2):63-66.
48. Lin B, Morris DW, Chou JY: Hepatocyte nuclear factor 1alpha is an accessory factor required for activation of glucose-6-phosphatase gene transcription by glucocorticoids. DNA Cell Biol 1998, 17(11):967-974.
49. Kalinyak JE, Perlman AJ: Tissue-specific regulation of angiotensinogen mRNA accumulation by dexamethasone. J Biol Chem 1987, 262(1):460-464.
50. Slieker LJ, Sloop KW, Surface PL, Kriauciunas A, LaQuier F, Manetta J, Bue-Valleskey J, Stephens TW: Regulation of expression of ob mRNA and protein by glucocorticoids and cAMP. J Biol Chem 1996, 271(10):5301-5304.
51. Ensler K, Mohammadieh M, Broijersen A, Angelin B, Gafvels M: Dexamethasone stimulates very low density lipoprotein (VLDL) receptor gene expression in differentiating 3T3-L1 cells. Biochim Biophys Acta 2002, 1581(1-2):36-48.
52. Olswang Y, Blum B, Cassuto H, Cohen H, Biberman Y, Hanson RW, Reshef L: Glucocorticoids repress transcription of phosphoenolpyruvate carboxykinase (GTP) gene in adipocytes by inhibiting its C/EBP-mediated activation. J Biol Chem 2003, 278(15):12929-12936.
53. Zilberfarb V, Siquier K, Strosberg AD, Issad T: Effect of dexamethasone on adipocyte differentiation markers and tumour necrosis factor-alpha expression in human PAZ6 cells. Diabetologia 2001, 44(3):377-386.
54. Stromstedt PE, Poellinger L, Gustafsson JA, Carlstedt-Duke J: The glucocorticoid receptor binds to a sequence overlapping the TATA box of the human osteocalcin promoter: a potential mechanism for negative regulation. Mol Cell Biol 1991, 11(6):3379-3383.
55. Meyer T, Carlstedt-Duke J, Starr DB: A weak TATA box is a prerequisite for glucocorticoid-dependent repression of the osteocalcin gene. J Biol Chem 1997, 272(49):30709-30714.
56. Malkoski SP, Dorin RI: Composite glucocorticoid regulation at a functionally defined negative glucocorticoid response element of the human corticotropin-releasing hormone gene. Mol Endocrinol 1999, 13(10):1629-1644.
57. Charron J, Drouin J: Glucocorticoid inhibition of transcription from episomal proopiomelanocortin gene promoter. Proc Natl Acad Sci U S A 1986, 83(23):8903-8907.
58. Drouin J, Sun YL, Chamberland M, Gauthier Y, De Lean A, Nemer M, Schmidt TJ: Novel glucocorticoid receptor complex with DNA element of the hormone-repressed POMC gene. EMBO J 1993, 12(1):145-156.
59. Sakai DD, Helms S, Carlstedt-Duke J, Gustafsson JA, Rottman FM, Yamamoto KR: Hormone-mediated repression: a negative glucocorticoid response element from the bovine prolactin gene. Genes Dev 1988, 2(9):1144-1154.
60. Diamond MI, Miner JN, Yoshinaga SK, Yamamoto KR: Transcription factor interactions: selectors of positive or negative regulation from a single DNA element. Science 1990, 249(4974):1266-1272.
61. Mordacq JC, Linzer DI: Co-localization of elements required for phorbol ester stimulation and glucocorticoid repression of proliferin gene expression. Genes Dev 1989, 3(6):760-769.
62. Akerblom IE, Slater EP, Beato M, Baxter JD, Mellon PL: Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer. Science 1988, 241(4863):350-353.
63. Chatterjee VK, Madison LD, Mayo S, Jameson JL: Repression of the human glycoprotein hormone alpha-subunit gene by glucocorticoids: evidence for receptor interactions with limiting transcriptional activators. Mol Endocrinol 1991, 5(1):100-110.
64. Waage A, Slupphaug G, Shalaby R: Glucocorticoids inhibit the production of IL6 from monocytes, endothelial cells and fibroblasts. Eur J Immunol 1990, 20(11):2439-2443.
65. Mukaida N, Morita M, Ishikawa Y, Rice N, Okamoto S, Kasahara T, Matsushima K: Novel mechanism of glucocorticoid-mediated gene repression. Nuclear factor-kappa B is target for glucocorticoid-mediated interleukin 8 gene repression. J Biol Chem 1994, 269(18):13289-13295.
66. Yang-Yen HF, Chambard JC, Sun YL, Smeal T, Schmidt TJ, Drouin J, Karin M: Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 1990, 62(6):1205-1215.
67. Andrew R, Gale CR, Walker BR, Seckl JR, Martyn CN: Glucocorticoid metabolism and the Metabolic Syndrome: associations in an elderly cohort. Exp Clin Endocrinol Diabetes 2002, 110(6):284-290.
68. Rosmond R, Dallman MF, Bjorntorp P: Stress-related cortisol secretion in men: relationships with abdominal obesity and endocrine, metabolic and hemodynamic abnormalities. J Clin Endocrinol Metab 1998, 83(6):1853-1859.
69. Walker BR, Phillips DI, Noon JP, Panarelli M, Andrew R, Edwards HV, Holton DW, Seckl JR, Webb DJ, Watt GC: Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension 1998, 31(4):891-895.
70. Reynolds RM, Walker BR, Syddall HE, Andrew R, Wood PJ, Whorwood CB, Phillips DI: Altered control of cortisol secretion in adult men with low birth weight and cardiovascular risk factors. J Clin Endocrinol Metab 2001, 86(1):245-250.
71. Filipovsky J, Ducimetiere P, Eschwege E, Richard JL, Rosselin G, Claude JR: The relationship of blood pressure with glucose, insulin, heart rate, free fatty acids and plasma cortisol levels according to degree of obesity in middle-aged men. J Hypertens 1996, 14(2):229-235.
72. Strain GW, Zumoff B, Kream J, Strain JJ, Levin J, Fukushima D: Sex difference in the influence of obesity on the 24 hr mean plasma concentration of cortisol. Metabolism 1982, 31(3):209-212.
73. Moyer AE, Rodin J, Grilo CM, Cummings N, Larson LM, Rebuffe-Scrive M: Stress-induced Cortisol response and fat distribution in women. Obes Res 1994, 2:255-262.
74. Epel EE, Moyer AE, Martin CD, Macary S, Cummings N, Rodin J, Rebuffe-Scrive M: Stress-induced cortisol, mood, and fat distribution in men. Obes Res 1999, 7(1):9-15.
75. Ljung T, Andersson B, Bengtsson BA, Bjorntorp P, Marin P: Inhibition of cortisol secretion by dexamethasone in relation to body fat distribution: a dose-response study. Obes Res 1996, 4(3):277-282.
76. Marin P, Darin N, Amemiya T, Andersson B, Jern S, Bjorntorp P: Cortisol secretion in relation to body fat distribution in obese premenopausal women. Metabolism 1992, 41(8):882-886.
77. Pasquali R, Cantobelli S, Casimirri F, Capelli M, Bortoluzzi L, Flamia R, Labate AM, Barbara L: The hypothalamic-pituitary-adrenal axis in obese women with different patterns of body fat distribution. J Clin Endocrinol Metab 1993, 77(2):341-346.
78. Dimitriou T, Maser-Gluth C, Remer T: Adrenocortical activity in healthy children is associated with fat mass. Am J Clin Nutr 2003, 77(3):731-736.
79. Reinehr T, Andler W: Cortisol and its relation to insulin resistance before and after weight loss in obese children. Horm Res 2004, 62(3):107-112.
80. Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, Connell JM: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 1999, 33(6):1364-1368.
81. Reynolds RM, Walker BR, Syddall HE, Whorwood CB, Wood PJ, Phillips DI: Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture. J Clin Endocrinol Metab 2001, 86(3):1149-1153.
82. Stolk RP, Lamberts SW, de Jong FH, Pols HA, Grobbee DE: Gender differences in the associations between cortisol and insulin in healthy subjects. J Endocrinol 1996, 149(2):313-318.
83. Shimomura Y, Bray GA, Lee M: Adrenalectomy and steroid treatment in obese (ob/ob) and diabetic (db/db) mice. Horm Metab Res 1987, 19(7):295-299.
84. Freedman MR, Horwitz BA, Stern JS: Effect of adrenalectomy and glucocorticoid replacement on development of obesity. Am J Physiol 1986, 250(4 Pt 2):R595-R607.
85. Mantha L, Palacios E, Deshaies Y: Modulation of triglyceride metabolism by glucocorticoids in diet-induced obesity. Am J Physiol 1999, 277(2 Pt 2):R455-R464.
86. Mantha L, Deshaies Y: Energy intake-independent modulation of triglyceride metabolism by glucocorticoids in the rat. Am J Physiol Regul Integr Comp Physiol 2000, 278(6):R1424-R1432.
87. Diamant S, Shafrir E: Modulation of the activity of insulin-dependent enzymes of lipogenesis by glucocorticoids. Eur J Biochem 1975, 53(2):541-546.
88. Wang CN, McLeod RS, Yao Z, Brindley DN: Effects of dexamethasone on the synthesis, degradation, and secretion of apolipoprotein B in cultured rat hepatocytes. Arterioscler Thromb Vasc Biol 1995, 15(9):1481-1491.
89. Itoh S, Igarashi M, Tsukada Y, Ichinoe A: Nonalcoholic fatty liver with alcoholic hyalin after long-term glucocorticoid therapy. Acta Hepatogastroenterol (Stuttg) 1977, 24(6):415-418.
90. Nanki T, Koike R, Miyasaka N: Subacute severe steatohepatitis during prednisolone therapy for systemic lupus erythematosis. Am J Gastroenterol 1999, 94(11):3379.
91. Dourakis SP, Sevastianos VA, Kaliopi P: Acute severe steatohepatitis related to prednisolone therapy. Am J Gastroenterol 2002, 97(4):1074-1075.
92. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI: Mechanism of hepatic insulin resistance in nonalcoholic fatty liver disease. J Biol Chem 2004, 279(31):32345-32353.
93. Seppala-Lindroos A, Vehkavaara S, Hakkinen AM, Goto T, Westerbacka J, Sovijarvi A, Halavaara J, Yki-Jarvinen H: Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 2002, 87(7):3023-3028.
94. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N: Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med 1999, 107(5):450-455.
95. Tiikkainen M, Tamminen M, Hakkinen AM, Bergholm R, Vehkavaara S, Halavaara J, Teramo K, Rissanen A, Yki-Jarvinen H: Liver-fat accumulation and insulin resistance in obese women with previous gestational diabetes. Obes Res 2002, 10(9):859-867.
96. Nguyen-Duy TB, Nichaman MZ, Church TS, Blair SN, Ross R: Visceral fat and liver fat are independent predictors of metabolic risk factors in men. Am J Physiol Endocrinol Metab 2003, 284(6):E1065-E1071.
97. Friedman JE, Yun JS, Patel YM, McGrane MM, Hanson RW: Glucocorticoids regulate the induction of phosphoenolpyruvate carboxykinase (GTP) gene transcription during diabetes. J Biol Chem 1993, 268(17):12952-12957.
98. Argaud D, Zhang Q, Pan W, Maitra S, Pilkis SJ, Lange AJ: Regulation of rat liver glucose-6-phosphatase gene expression in different nutritional and hormonal states: gene structure and 5′-flanking sequence. Diabetes 1996, 45(11):1563-1571.
99. Hauner H, Schmid P, Pfeiffer EF: Glucocorticoids and insulin promote the differentiation of human adipocyte precursor cells into fat cells. J Clin Endocrinol Metab 1987, 64(4):832-835.
100. Hauner H, Entenmann G, Wabitsch M, Gaillard D, Ailhaud G, Negrel R, Pfeiffer EF: Promoting effect of glucocorticoids on the differentiation of human adipocyte precursor cells cultured in a chemically defined medium. J Clin Invest 1989, 84(5):1663-1670.
101. Olefsky JM: Effect of dexamethasone on insulin binding, glucose transport, and glucose oxidation of isolated rat adipocytes. J Clin Invest 1975, 56(6):1499-1508.
102. Carter-Su C, Okamoto K: Effect of insulin and glucocorticoids on glucose transporters in rat adipocytes. Am J Physiol 1987, 252(4 Pt 1):E441-E453.
103. Horner HC, Munck A, Lienhard GE: Dexamethasone causes translocation of glucose transporters from the plasma membrane to an intracellular site in human fibroblasts. J Biol Chem 1987, 262(36):17696-17702.
104. Oda N, Nakai A, Mokuno T, Sawai Y, Nishida Y, Mano T, Asano K, Itoh Y, Kotake M, Kato S, Masunaga R, Iwase K, Tsujimura T, Itoh M, Kawabe T, Nagasaka A: Dexamethasone-induced changes in glucose transporter 4 in rat heart muscle, skeletal muscle and adipocytes. Eur J Endocrinol 1995, 133(1):121-126.
105. Dimitriadis G, Leighton B, Parry-Billings M, Sasson S, Young M, Krause U, Bevan S, Piva T, Wegener G, Newsholme EA: Effects of glucocorticoid excess on the sensitivity of glucose transport and metabolism to insulin in rat skeletal muscle. Biochem J 1997, 321(Pt 3):707-712.
106. Grunfeld C, Jones DS: Glucocorticoid-induced insulin resistance in vitro: inhibition of insulin-stimulated methylaminoisobutyric acid uptake. Horm Metab Res 1986, 18(3):149-152.
107. Ekstrand A, Saloranta C, Ahonen J, Gronhagen-Riska C, Groop LC: Reversal of steroid-induced insulin resistance by a nicotinic-acid derivative in man. Metabolism 1992, 41(7):692-697.
108. Guillaume-Gentil C, Assimacopoulos-Jeannet F, Jeanrenaud B: Involvement of non-esterified fatty acid oxidation in glucocorticoid-induced peripheral insulin resistance in vivo in rats. Diabetologia 1993, 36(10):899-906.
109. Lambillotte C, Gilon P, Henquin JC: Direct glucocorticoid inhibition of insulin secretion. An in vitro study of dexamethasone effects in mouse islets. J Clin Invest 1997, 99(3):414-423.
110. Hollingdal M, Juhl CB, Dall R, Sturis J, Veldhuis JD, Schmitz O, Porksen N: Glucocorticoid induced insulin resistance impairs basal but not glucose entrained high-frequency insulin pulsatility in humans. Diabetologia 2002, 45(1):49-55.
111. Lloyd-MacGilp SA, Nelson SM, Florin M, Lo M, McKinnell J, Sassard J, Kenyon CJ: 11β-hydroxysteroid dehydrogenase and corticosteroid action in lyon hypertensive rats. Hypertension 1999, 34(5):1123-1128.
112. Brem AS, Bina RB, King TC, Morris DJ: Localization of 2 11β-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension 1998, 31(1 Pt 2):459-462.
113. Brem AS, Bina RB, Hill N, Alia C, Morris DJ: Effects of licorice derivatives on vascular smooth muscle function. Life Sci 1997, 60(3):207-214.
114. Walker BR, Sang KS, Williams BC, Edwards CR: Direct and indirect effects of carbenoxolone on responses to glucocorticoids and noradrenaline in rat aorta. J Hypertens 1994, 12(1):33-39.
115. Kuhn RW, Green AL, Raymoure WJ, Siiteri PK: Immunocytochemical localization of corticosteroid-binding globulin in rat tissues. J Endocrinol 1986, 108(1):31-36.
116. Werthamer S, Samuels AJ, Amaral L: Identification and partial purification of "transcortin"-like protein within human lymphocytes. J Biol Chem 1973, 248(18):6398-6407.
117. Fernandez-Real JM, Pugeat M, Grasa M, Broch M, Vendrell J, Brun J, Ricart W: Serum corticosteroid-binding globulin concentration and insulin resistance syndrome: a population study. J Clin Endocrinol Metab 2002, 87(10):4686-4690.
118. Ousova O, Guyonnet-Duperat V, Iannuccelli N, Bidanel JP, Milan D, Genet C, Llamas B, Yerle M, Gellin J, Chardon P, Emptoz-Bonneton A, Pugeat M, Mormede P, Moisan MP: Corticosteroid binding globulin: a new target for cortisol-driven obesity. Mol Endocrinol 2004, 18(7):1687-1696.
119. Torpy DJ, Bachmann AW, Grice JE, Fitzgerald SP, Phillips PJ, Whitworth JA, Jackson RV: Familial corticosteroid-binding globulin deficiency due to a novel null mutation: association with fatigue and relative hypotension. J Clin Endocrinol Metab 2001, 86(8):3692-3700.
120. Emptoz-Bonneton A, Cousin P, Seguchi K, Avvakumov GV, Bully C, Hammond GL, Pugeat M: Novel human corticosteroid-binding globulin variant with low cortisol-binding affinity. J Clin Endocrinol Metab 2000, 85(1):361-367.
121. Joyner JM, Hutley LJ, Bachmann AW, Torpy DJ, Prins JB: Greater replication and differentiation of preadipocytes in inherited corticosteroid-binding globulin deficiency. Am J Physiol Endocrinol Metab 2003, 284(5):E1049-E1054.
122. Grasa MM, Cabot C, Fernandez-Lopez JA, Remesar X, Alemany M: Modulation of corticosterone availability to white adipose tissue of lean and obese Zucker rats by corticosteroid-binding globulin. Horm Metab Res 2001, 33(7):407-411.
123. Tannin GM, Agarwal AK, Monder C, New MI, White PC: The human gene for 11β-hydroxysteroid dehydrogenase. Structure, tissue distribution, and chromosomal localization. J Biol Chem 1991, 266(25):16653-16658.
124. Ozols J: Lumenal orientation and post-translational modifications of the liver microsomal 11β-hydroxysteroid dehydrogenase. J Biol Chem 1995, 270(5):2305-2312. Erratum in: J Biol Chem 1995, 270(17):10360
125. Odermatt A, Arnold P, Stauffer A, Frey BM, Frey FJ: The N-terminal anchor sequences of 11β-hydroxysteroid dehydrogenases determine their orientation in the endoplasmic reticulum membrane. J Biol Chem 1999, 274(40):28762-28770.
126. Kotelevtsev Y, Brown RW, Fleming S, Kenyon C, Edwards CR, Seckl JR, Mullins JJ: Hypertension in mice lacking 11β-hydroxysteroid dehydrogenase type 2. J Clin Invest 1999, 103(5):683-689.
127. Liu Y, Nakagawa Y, Wang Y, Li R, Li X, Ohzeki T, Friedman TC: Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 2003, 52(6):1409-1416.
128. Aoki K, Homma M, Hirano T, Oka K, Satoh S, Mukasa K, Ito S, Sekihara H: mRNA and enzyme activity of hepatic 11β-hydroxysteroid dehydrogenase type 1 are elevated in C57BL/KsJ-db/db mice. Life Sci 2001, 69(21):2543-2549.
129. Livingstone DE, Kenyon CJ, Walker BR: Mechanisms of dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in obese Zucker rats. J Endocrinol 2000, 167(3):533-539.
130. Livingstone DE, Jones GC, Smith K, Jamieson PM, Andrew R, Kenyon CJ, Walker BR: Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 2000, 141(2):560-563.
131. Rask E, Olsson T, Soderberg S, Andrew R, Livingstone DE, Johnson O, Walker BR: Tissue-specific dysregulation of cortisol metabolism in human obesity. J Clin Endocrinol Metab 2001, 86(3):1418-1421.
132. Stewart PM, Boulton A, Kumar S, Clark PM, Shackleton CH: Cortisol metabolism in human obesity: impaired cortisone - >cortisol conversion in subjects with central adiposity. J Clin Endocrinol Metab 1999, 84(3):1022-1027.
133. Rask E, Walker BR, Soderberg S, Livingstone DE, Eliasson M, Johnson O, Andrew R, Olsson T: Tissue-specific changes in peripheral cortisol metabolism in obese women: increased adipose 11β-hydroxysteroid dehydrogenase type 1 activity. J Clin Endocrinol Metab 2002, 87(7):3330-3336.
134. Wake DJ, Rask E, Livingstone DE, Soderberg S, Olsson T, Walker BR: Local and systemic impact of transcriptional up-regulation of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue in human obesity. J Clin Endocrinol Metab 2003, 88(8):3983-3988.
135. Valsamakis G, Anwar A, Tomlinson JW, Shackleton CH, McTernan PG, Chetty R, Wood PJ, Banerjee AK, Holder G, Barnett AH, Stewart PM, Kumar S: 11β-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus. J Clin Endocrinol Metab 2004, 89(9):4755-4761.
136. Paulmyer-Lacroix O, Boullu S, Oliver C, Alessi MC, Grino M: Expression of the mRNA coding for 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue from obese patients: an in situ hybridization study. J Clin Endocrinol Metab 2002, 87(6):2701-2705.
137. Lindsay RS, Wake DJ, Nair S, Bunt J, Livingstone DE, Permana PA, Tataranni PA, Walker BR: Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians. J Clin Endocrinol Metab 2003, 88(6):2738-2744.
138. Kannisto K, Pietilainen KH, Ehrenborg E, Rissanen A, Kaprio J, Hamsten A, Yki-Jarvinen H: Overexpression of 11β-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins. J Clin Endocrinol Metab 2004, 89(9):4414-4421.
139. Bujalska IJ, Kumar S, Stewart PM: Does central obesity reflect "Cushing's disease of the omentum"? Lancet 1997, 349(9060):1210-1213.
140. Tomlinson JW, Sinha B, Bujalska I, Hewison M, Stewart PM: Expression of 11β-hydroxysteroid dehydrogenase type 1 in adipose tissue is not increased in human obesity. J Clin Endocrinol Metab 2002, 87(12):5630-5635.
141. Livingstone DE, Walker BR: Is 11β-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats. J Pharmacol Exp Ther 2003, 305(1):167-172.
142. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000, 356(9239):1423-1430.
143. Miller KK, Daly PA, Sentochnik D, Doweiko J, Samore M, Basgoz NO, Grinspoon SK: Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis 1998, 27(1):68-72.
144. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR, Yki-Jarvinen H: In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Cushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004, 47(10):1668-1671.
145. Kotelevtsev Y, Holmes MC, Burchell A, Houston PM, Schmoll D, Jamieson P, Best R, Brown R, Edwards CR, Seckl JR, Mullins JJ: 11β-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997, 94(26):14924-14929.
146. Morton NM, Paterson JM, Masuzaki H, Holmes MC, Staels B, Fievet C, Walker BR, Flier JS, Mullins JJ, Seckl JR: Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11β-hydroxysteroid dehydrogenase type 1-deficient mice. Diabetes 2004, 53(4):931-938.
147. Morton NM, Holmes MC, Fievet C, Staels B, Tailleux A, Mullins JJ, Seckl JR: Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11β-hydroxysteroid dehydrogenase type 1 null mice. J Biol Chem 2001, 276(44):41293-41300.
148. Justesen J, Mosekilde L, Holmes M, Stenderup K, Gasser J, Mullins JJ, Seckl JR, Kassem M: Mice deficient in 11β-hydroxysteroid dehydrogenase type 1 lack bone marrow adipocytes, but maintain normal bone formation. Endocrinology 2004, 145(4):1916-1925.
149. Harris HJ, Kotelevtsev Y, Mullins JJ, Seckl JR, Holmes MC: Intracellular regeneration of glucocorticoids by 11β-hydroxysteroid dehydrogenase (11β-HSD)-1 plays a key role in regulation of the hypothalamic-pituitary- adrenal axis: analysis of 11β-HSD-1-deficient mice. Endocrinology 2001, 142(1):114-120.
150. Yau JL, Noble J, Kenyon CJ, Hibberd C, Kotelevtsev Y, Mullins JJ, Seckl JR: Lack of tissue glucocorticoid reactivation in 11β-hydroxysteroid dehydrogenase type 1 knockout mice ameliorates age-related learning impairments. Proc Natl Acad Sci USA 2001, 98(8):4716-4721.
151. Masuzaki H, Paterson J, Shinyama H, Morton NM, Mullins JJ, Seckl JR, Flier JS: A transgenic model of visceral obesity and the metabolic syndrome. Science 2001, 294(5549):2166-2170.
152. Masuzaki H, Yamamoto H, Kenyon CJ, Elmquist JK, Morton NM, Paterson JM, Shinyama H, Sharp MG, Fleming S, Mullins JJ, Seckl JR, Flier JS: Transgenic
153. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ: Metabolic syndrome without obesity: Hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci USA 2004, 101(18):7088-7093.
154. Phillipou G, Higgins BA: A new defect in the peripheral conversion of cortisone to cortisol. J Steroid Biochem 1985, 22(3):435-436.
155. Jamieson A, Wallace AM, Andrew R, Nunez BS, Walker BR, Fraser R, White PC, Connell JM: Apparent cortisone reductase deficiency: a functional defect in 11β-hydroxysteroid dehydrogenase type 1. J Clin Endocrinol Metab 1999, 84(10):3570-3574.
156. Biason-Lauber A, Suter SL, Shackleton CH, Zachmann M: Apparent cortisone reductase deficiency: a rare cause of hyperandrogenemia and hypercortisolism. Horm Res 2000, 53(5):260-266.
157. Tomlinson JW, Draper N, Mackie J, Johnson AP, Holder G, Wood P, Stewart PM: Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion. J Clin Endocrinol Metab 2002, 87(1):57-62.
158. Malunowicz EM, Romer TE, Urban M, Bossowski A: 11β-hydroxysteroid dehydrogenase type 1 deficiency ('apparent cortisone reductase deficiency') in a 6-year-old boy. Horm Res 2003, 59(4):205-210.
159. Draper N, Echwald SM, Lavery GG, Walker EA, Fraser R, Davies E, Sorensen TI, Astrup A, Adamski J, Hewison M, Connell JM, Pedersen O, Stewart PM: Association studies between microsatellite markers within the gene encoding human 11β-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism. J Clin Endocrinol Metab 2002, 87(11):4984-4990.
160. Gelernter-Yaniv L, Feng N, Sebring NG, Hochberg Z, Yanovski JA: Associations between a polymorphism in the 11β-hydroxysteroid dehydrogenase type 1 gene and body composition. Int J Obes Relat Metab Disord 2003, 27(8):983-986.
161. Davani B, Khan A, Hult M, Martensson E, Okret S, Efendic S, Jornvall H, Oppermann UC: Type 1 11β-hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets. J Biol Chem 2000, 275(45):34841-34844.
162. Duplomb L, Lee Y, Wang MY, Park BH, Takaishi K, Agarwal AK, Unger RH: Increased expression and activity of 11β-HSD-1 in diabetic islets and prevention with troglitazone. Biochem Biophys Res Commun 2004, 313(3):594-599.
163. Sampath-Kumar R, Yu M, Khalil MW, Yang K: Metyrapone is a competitive inhibitor of 11β-hydroxysteroid dehydrogenase type 1 reductase. J Steroid Biochem Mol Biol 1997, 62(2-3):195-199.
164. Hult M, Jornvall H, Oppermann UC: Selective inhibition of human type 1 11β-hydroxysteroid dehydrogenase by synthetic steroids and xenobiotics. FEBS Lett 1998, 441(1):25-28.
165. Diederich S, Grossmann C, Hanke B, Quinkler M, Herrmann M, Bahr V, Oelkers W: In the search for specific inhibitors of human 11β- hydroxysteroid-dehydrogenases (11β-HSDs): chenodeoxycholic acid selectively inhibits 11β-HSD-1. Eur J Endocrinol 2000, 142(2):200-207.
166. Stauffer AT, Rochat MK, Dick B, Frey FJ, Odermatt A: Chenodeoxycholic acid and deoxycholic acid inhibit 11β-hydroxysteroid dehydrogenase type 2 and cause cortisol-induced transcriptional activation of the mineralocorticoid receptor. J Biol Chem 2002, 277(29):26286-26292.
167. Morris DJ, Souness GW, Latif SA, Hardy MP, Brem AS: Effect of chenodeoxycholic acid on 11β-hydroxysteroid dehydrogenase in various target tissues. Metabolism 2004, 53(6):811-816.
168. Andrews RC, Rooyackers O, Walker BR: Effects of the 11β- hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes. J Clin Endocrinol Metab 2003, 88(1):285-291.
169. Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR: 11β-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci USA 2004, 101(17):6734-6739.
170. Barf T, Vallgarda J, Emond R, Haggstrom C, Kurz G, Nygren A, Larwood V, Mosialou E, Axelsson K, Olsson R, Engblom L, Edling N, Ronquist-Nii Y, Ohman B, Alberts P, Abrahmsen L: Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs: Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1. J Med Chem 2002, 45(18):3813-3815.
171. Alberts P, Engblom L, Edling N, Forsgren M, Klingstrom G, Larsson C, Ronquist-Nii Y, Ohman B, Abrahmsen L: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice. Diabetologia 2002, 45(11):1528-1532.
172. Alberts P, Nilsson C, Selen G, Engblom LO, Edling NH, Norling S, Klingstrom G, Larsson C, Forsgren M, Ashkzari M, Nilsson CE, Fiedler M, Bergqvist E, Ohman B, Bjorkstrand E, Abrahmsen LB: Selective inhibition of 11β-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains. Endocrinology 2003, 144(11):4755-4762.
173. Hermanowski-Vosatka A, Mundt S, Nunes C, Strowski M, Li Z, Frazier E, Le Grand C, Chen H, Robertson N, Metzger J, Strack A, Olson S, Schaeffer J, Wright SD, Balkovec J, Thieringer R: 11β-HSD1 inhibition ameliorates metabolic syndrome in mice. The Keystone Symposia for Adipogenesis and Obesity (X2) 2004 Abstract Book: 4-10 March 2004; Banff, Alberta, Canada 2004:194. abstract 215
174. Friedman JE, Sun Y, Ishizuka T, Farrell CJ, McCormack SE, Herron LM, Hakimi P, Lechner P, Yun JS: Phosphoenolpyruvate carboxykinase (GTP) gene transcription and hyperglycemia are regulated by glucocorticoids in genetically obese db/db transgenic mice. J Biol Chem 1997, 272(50):31475-31481.
175. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI: Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000, 49(12):2063-2069.
176. Gruol DJ, Altschmied J: Synergistic induction of apoptosis with glucocorticoids and 3′,5′-cyclic adenosine monophosphate reveals agonist activity by RU 486. Mol Endocrinol 1993, 7(1):104-113.
177. Garrel DR, Moussali R, De Oliveira A, Lesiege D, Lariviere F: RU 486 prevents the acute effects of cortisol on glucose and leucine metabolism. J Clin Endocrinol Metab 1995, 80(2):379-385.
178. Lamberts SW, Koper JW, de Jong FH: The endocrine effects of long-term treatment with mifepristone (RU 486). J Clin Endocrinol Metab 1991, 73(1):187-191.
179. Kim PJ, Cole MA, Kalman BA, Spencer RL: Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies. J Steroid Biochem Mol Biol 1998, 67(3):213-222.
180. von Geldern TW, Tu N, Kym PR, Link JT, Jae HS, Lai C, Apelqvist T, Rhonnstad P, Hagberg L, Koehler K, Grynfarb M, Goos-Nilsson A, Sandberg J, Osterlund M, Barkhem T, Hoglund M, Wang J, Fung S, Wilcox D, Nguyen P, Jakob C, Hutchins C, Farnegardh M, Kauppi B, Ohman L, Jacobson PB: Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes. J Med Chem 2004, 47(17):4213-4230.